The Clinical Analysis Of Haploidentical Peripheral Blood Stem Cell Transplantation Combined With Unrelated Cord Blood In Hematologic Malignancy Patients

Objective:To explore the safety and efficacy of haploidentical peripheral blood stem cell transplantation(Haplo-PBSCT)combined with unrelated cord blood(UCB)for hematological malignancies.Method:The outcomes of 80 patients with hematologic malignancies who received haplo-PBSCT combined with UCB from March 2017 to June 2020 were analyzed in this retrospective study.Kapla-n-Meier was used to estimate long-term survival outcomes,such as overall survival(OS),disease-free survival(DFS),GVHD/relapse free survival(GRFS).The cumulative incidence of implantation,graft vers-us host disease(GVHD),non-relapse mortality(NRM)and relapse w-ere calculated using a competing risk model.Results:The median time for neutrophil and platelet engraftmen-t was 13(range: 8-22)days and 14(range: 8-103)days,respectively.The cumulative incidence of neutrophil engraftment at 30 days was100%,and the 100-day cumulative incidence of platelet engraftmentwas 95%.All patients achieved complete haploidentical peripheral b-lood stem cell engraftment,and no cord blood chimerism was obse-rved.The cumulative incidence of grades II-IV and grades III-IV a-cute GVHD on100-day was 26.3±0.0% and 5.0±0.2%,respectively.The cumulative incidence of chronic GVHD and moderate-severe c-hronic GVHD at3-year was 43.3±0.3% and 16.0±0.2%,respectively.The 3-year cumulative incidence of relapse and NRM was 18.8±0.2% and17.8±0.2%,respectively.The 3-year probabilities of OS,DF-S,GRFS were 77.6±5.0%,63.4±6.1%,and 55.5±6.1%,respectively.Conclusion:These satisfying results suggested that haplo-PBSCT combined with UCB is an alternative transplantation protocol for hematologic malignancies.